CR9410A - Metodos para el tratamiento de abuso y dependencia de sustancias - Google Patents

Metodos para el tratamiento de abuso y dependencia de sustancias

Info

Publication number
CR9410A
CR9410A CR9410A CR9410A CR9410A CR 9410 A CR9410 A CR 9410A CR 9410 A CR9410 A CR 9410A CR 9410 A CR9410 A CR 9410A CR 9410 A CR9410 A CR 9410A
Authority
CR
Costa Rica
Prior art keywords
treatment
methods
abuse
dependence
substances
Prior art date
Application number
CR9410A
Other languages
English (en)
Inventor
Sabnani Sanjay
Wesson Donald
Dunn Joseph
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of CR9410A publication Critical patent/CR9410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion es concerniente con metodos de y composiciones para el tratamiento y alivio de sintomas y enfermedad asociados con indicaciones provocadas por un impulso fisiologico a aliviar una sensacion de ansiedad. Mas especificamente, la presente invencion es concerniente con metodos de y composiciones para el tratamiento y alivio de sintomas asociados con abuso y abandono de sustancia.
CR9410A 2005-04-07 2007-10-02 Metodos para el tratamiento de abuso y dependencia de sustancias CR9410A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US72897905P 2005-10-21 2005-10-21
US72901305P 2005-10-21 2005-10-21

Publications (1)

Publication Number Publication Date
CR9410A true CR9410A (es) 2008-02-21

Family

ID=37087555

Family Applications (2)

Application Number Title Priority Date Filing Date
CR9410A CR9410A (es) 2005-04-07 2007-10-02 Metodos para el tratamiento de abuso y dependencia de sustancias
CR9413A CR9413A (es) 2005-04-07 2007-10-03 Metodos para el tratamiento de alteraciones relacionadas con ansiedad

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR9413A CR9413A (es) 2005-04-07 2007-10-03 Metodos para el tratamiento de alteraciones relacionadas con ansiedad

Country Status (12)

Country Link
US (3) US20080207601A1 (es)
EP (3) EP1868593A2 (es)
JP (3) JP2008538748A (es)
KR (2) KR20080004581A (es)
AU (3) AU2006235318A1 (es)
BR (2) BRPI0609744A2 (es)
CA (3) CA2604887A1 (es)
CR (2) CR9410A (es)
IL (2) IL186450A0 (es)
MX (2) MX2007012355A (es)
NO (2) NO20075161L (es)
WO (3) WO2006110642A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2604887A1 (en) * 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
EP2164324B1 (en) 2007-06-15 2014-08-13 University Of Florida Research Foundation Therapeutic compounds
KR20100121463A (ko) 2007-12-17 2010-11-17 라보팜 인코포레이트 오용 예방적 방출 제어형 제제
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
JP5667575B2 (ja) 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
EP2398475B1 (en) * 2009-02-20 2017-12-13 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
WO2011073985A1 (en) * 2009-12-14 2011-06-23 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
WO2012006683A1 (en) * 2010-07-16 2012-01-19 Controlled Release Technologies Pty Ltd Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
RU2019104004A (ru) 2012-01-23 2019-03-07 Сейдж Терапьютикс, Инк. Лекарственные формы нейроактивных стероидов и способы лечения нарушений цнс
ES2902684T3 (es) * 2012-08-21 2022-03-29 Sage Therapeutics Inc Alopregnanolona para el tratamiento del estado epiléptico refractario
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
SG11201504848QA (en) * 2012-12-18 2015-07-30 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
WO2015200766A2 (en) * 2014-06-26 2015-12-30 The Johns Hopkins University Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
TWI798173B (zh) 2016-03-08 2023-04-11 美商賽吉醫療公司 神經活性類固醇，其組合物及用途
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
EP3565528A1 (en) * 2017-01-09 2019-11-13 Asarina Pharma AB Injectable suspensions
ES2897790T3 (es) * 2017-03-28 2022-03-02 Ldn Pharma Ltd Un agente que aumenta la expresión del agonista asociado a Bcl2 de la muerte celular para el tratamiento del cáncer
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
WO2019055939A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING
WO2019055942A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE
WO2019060171A1 (en) * 2017-09-20 2019-03-28 Calista Capital, Llc METHOD FOR STOPPING TOBACCO
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
KR20200140832A (ko) * 2018-04-05 2020-12-16 아사리나 파마 에이피에스 물질 금단 장애를 치료하기 위한 gaba-a 길항제
JP2021521103A (ja) * 2018-04-06 2021-08-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 物質使用障害の処置におけるガボキサドールの使用
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
EP3937947A4 (en) * 2019-03-14 2022-11-16 Palmaya Pty Ltd TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM
HRP20231735T1 (hr) * 2019-08-26 2024-03-15 Period Pill Bv Liječenje simptoma izazvanih menstrualnim ciklusom

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
EP1024820A1 (en) * 1997-08-28 2000-08-09 Janus Pharmaceuticals, Inc. Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
AU4100699A (en) 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
EP1212051A4 (en) * 1999-08-27 2004-03-31 Merck & Co Inc METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
CN1486205A (zh) * 2001-01-17 2004-03-31 氟马西尼在用于酒依赖治疗药物制备中的应用
RU2322985C2 (ru) * 2001-02-15 2008-04-27 Хитиям, Инк. Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
GB0311859D0 (en) * 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CA2604887A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
EP1868593A2 (en) 2007-12-26
EP1901727A4 (en) 2009-11-11
KR20080004580A (ko) 2008-01-09
EP1868432A2 (en) 2007-12-26
WO2006110642A2 (en) 2006-10-19
WO2006110580A2 (en) 2006-10-19
WO2006110557A3 (en) 2009-04-16
MX2007012355A (es) 2008-01-16
US8012958B2 (en) 2011-09-06
CA2603519A1 (en) 2006-10-19
AU2006235234A1 (en) 2006-10-19
CA2603533A1 (en) 2006-10-19
NO20075161L (no) 2008-01-07
JP2008535850A (ja) 2008-09-04
CR9413A (es) 2008-01-21
US20080207601A1 (en) 2008-08-28
BRPI0610693A2 (pt) 2016-11-22
EP1901727A2 (en) 2008-03-26
EP1868432A4 (en) 2009-11-04
MX2007012353A (es) 2008-01-16
AU2006235257B2 (en) 2010-11-04
US20080280885A1 (en) 2008-11-13
WO2006110557A2 (en) 2006-10-19
WO2006110580A3 (en) 2007-08-16
IL186450A0 (en) 2008-01-20
AU2006235318A1 (en) 2006-10-19
JP2008538748A (ja) 2008-11-06
AU2006235257A1 (en) 2006-10-19
WO2006110642A3 (en) 2009-04-23
IL186447A0 (en) 2008-08-07
NO20075155L (no) 2008-01-07
KR20080004581A (ko) 2008-01-09
US20080255097A1 (en) 2008-10-16
BRPI0609744A2 (pt) 2010-04-27
CA2604887A1 (en) 2006-10-19
JP2008535852A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
CR9410A (es) Metodos para el tratamiento de abuso y dependencia de sustancias
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CR9601A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
GT200600045A (es) Derivados de piridizina y su uso como agentes terapeuticos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
UY30364A1 (es) Arilimidazolonas y ariltriazolonas sustituidas asi como su uso
UY28945A1 (es) Derivados de pirrolopiridina
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
HRP20070516A2 (en) Methods for treating infectious disease exacerbated asthma
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
WO2007142755A3 (en) Purine analogs
ZA200803659B (en) Use of complement pathway inhibitors to treat ocular disease
EA201300213A1 (ru) Применение ингибиторов dpp iv
BR112012000204A8 (pt) Composição farmacêutica em forma de dosagem unitária que compreende apomorfina e seu uso
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa